Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19.
Karl HagmanMagnus HedenstiernaJacob WidaeusEmelie ArvidssonBerit HammasLena GrillnerJan G JakobssonPatrik Gille-JohnsonJohan UrsingPublished in: The Journal of antimicrobial chemotherapy (2023)
Remdesivir treatment did not significantly change the duration of SARS-CoV-2 viraemia, decline of serum viral load, 60 day mortality or in-hospital adverse outcomes in patients with ≤10 days of symptoms at admission. Remdesivir appeared to reduce the duration of viraemia in a subgroup of patients with ≤7 days of symptoms at admission.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- emergency department
- cardiovascular events
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- coronavirus disease
- prognostic factors
- risk factors
- peritoneal dialysis
- cardiovascular disease
- sleep quality
- coronary artery disease
- type diabetes
- depressive symptoms
- combination therapy
- patient reported
- open label
- smoking cessation